Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.51 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27686945 | 0.98 | KDM4E (0.56) | KDM4EALDH1A1PKMCHRNA7CHRNB2 | |
| SCHEMBL31054426 | 0.94 | CHRNA7 (0.53) | KDM4EALDH1A1PKMCHRNA7CHRNB2 | |
| SCHEMBL9534698 | 0.94 | CHRNA7 (0.53) | KDM4EALDH1A1PKMCHRNA7CHRNB2 | |
| SCHEMBL24933229 | 0.90 | CHRNB2 (0.56) | KDM4EALDH1A1PKMCHRNA7CHRNB2 | |
| SCHEMBL38663623 | 0.82 | GBA1 (0.62) | KDM4EALDH1A1PKMCHRNA7CHRNB2 | |
| SCHEMBL2279484 | 0.82 | GBA1 (0.62) | KDM4EALDH1A1PKMCHRNA7CHRNB2 | |
| SCHEMBL13503878 | 0.82 | CHRNA7 (0.49) | KDM4EALDH1A1PKMCHRNA7CHRNB2 | |
| Hydrochloric Acid SCHEMBL3301662 | 0.81 | GBA1 (0.61) | KDM4EALDH1A1PKMCHRNA7CHRNB2 | |
| Ammonia Solution, Strong SCHEMBL5378833 | 0.81 | CHRNA7 (0.48) | KDM4EALDH1A1PKMCHRNA7CHRNB2 | |
| Hydrochloric Acid SCHEMBL18280120 | 0.81 | GBA1 (0.61) | KDM4EALDH1A1PKMCHRNA7CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12180221-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-12-31 | — | — | US | disclosed |
| CN-118084800-A | Compounds and uses thereof | 詹森药业有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118084801-A | Compounds and uses thereof | 詹森药业有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-112312913-B | Compounds and uses thereof | 詹森药业有限公司 | 2024-03-08 | — | — | CN | disclosed |
| US-20230078764-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-16 | — | — | US | disclosed |
| US-20220298168-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2022-09-22 | — | — | US | disclosed |
| CN-114174273-A | Compounds and uses thereof | 优曼尼蒂治疗公司 | 2022-03-11 | — | — | CN | disclosed |
| EP-3941908-A1 | COMPOUNDS AND USES THEREOF | Yumanity Therapeutics, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| CN-109550519-A | A kind of preparation method of phosphine ruthenium functionalized ion liquid and preparation method thereof, a kind of catalyst and 4- acetoxyl group butyraldehyde | 万华化学集团股份有限公司 | 2019-04-02 | — | — | CN | disclosed |
| CN-108802212-A | A kind of liquid phase detection method of lactation period Cefquinome sulfate breast injection related substances | 佛山市南海东方澳龙制药有限公司 | 2018-11-13 | — | — | CN | disclosed |
| CN-108802211-A | The liquid phase detection method of related substances in a kind of Cefquinome sulfate breast injection | 佛山市南海东方澳龙制药有限公司 | 2018-11-13 | — | — | CN | disclosed |
| CN-107431247-A | Non-aqueous electrolyte and non-aqueous secondary battery | 旭化成株式会社 | 2017-12-01 | — | — | CN | disclosed |
| CN-107406461-A | Heterocycle alkyne hydrocarbon derivative and its purposes as mGluR5 receptor modulators | 雷科尔达蒂爱尔兰有限公司 | 2017-11-28 | — | — | CN | disclosed |
| CN-103097391-B | Novel spiroheterocyclic compounds as mGlu5 antagonists | RECORDATI IRELAND LTD | 2015-04-08 | — | — | CN | disclosed |
| US-5622953-A | DRUG RESISTANT TO ANTICANCER CHEMOTHERAPEUTIC DRUG | BASF AKTIENGESELLSCHAFT (DE) | 1997-04-22 | — | — | US | disclosed |
| EP-0691962-A1 | 1-AMINO-3-PHENOXY PROPANE DERIVATIVES AS MODULATORS OF MULTI-DRUG RESISTANCE | BASF AKTIENGESELLSCHAFT (DE) | 1996-01-17 | — | — | EP | disclosed |
| WO-1994022842-A1 | 1-AMINO-3-PHENOXY PROPANE DERIVATIVES AS MODULATORS OF MULTI-DRUG RESISTANCE | BASF AKTIENGESELLSCHAFT (DE) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230078764-A1 | COMPOUNDS AND USES THEREOF | NLN, BDNF, NQO1 | KDM4E 1073/4885ALDH1A1 293/4885PKM 833/4885 |
| US-20220298168-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | KDM4E 2853/4885ALDH1A1 656/4885PKM 1304/4885 |
| US-12180221-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | KDM4E 2853/4885ALDH1A1 656/4885PKM 1304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.